India’s Union Health Ministry has proposed a sweeping change to how the country handles substandard medicines: instead of issuing a show-cause notice first and suspending a manufacturing licence later, regulators would be able to suspend that licence immediately the moment a government laboratory declares a drug Not of Standard Quality (NSQ) on one of five critical parameters.
The proposal is a draft amendment to the Drugs Rules, 1945, notified as G.S.R. 956(E) and dated 28 October 2026. It was published in the Gazette of India on 29 October 2026 and made public on 4 November 2026. Stakeholders have 30 days from publication to submit objections and suggestions.
📋 What the Draft Rules Actually Change
The draft inserts two new sub-rules into Rule 85 of the Drugs Rules, 1945. The operative text of the new sub-rule (2A) is explicit about both the trigger and the consequence:
on receipt of a certificate of test or analysis under the Act from Government Analyst for any drug with opinion that the drug is not of standard quality with respect to Assay/Dissolution/Related Substance/Impurity/Sterility, shall immediately suspend the manufacturing licence granted to manufacture the said drug and the licence shall remain suspended till the licencee carry out the effective route cause analysis and implement the Corrective Action and Preventive Action (CAPA) to the satisfaction of the licensing authority.
A consequential amendment applies the same mechanism to Rule 122O, which governs licences for imported drugs and for drugs manufactured under loan licence arrangements. Both routes now carry the identical immediate-suspension language.
The five triggering parameters
The draft is deliberately narrow. Suspension is triggered only by an NSQ finding on one of these five parameters, which the Ministry describes as “critical to determining the quality of medicines”:
- Assay — the measured amount of active ingredient against the labelled claim
- Dissolution — how the drug releases that active ingredient in the body
- Related substances — degradation products and process-related analogues of the active ingredient
- Impurity — contaminants present above prescribed limits
- Sterility — the absence of microbial contamination in sterile products
⚠️ Why the Ministry Says the Current System Is Too Slow
Under the existing Rule 85, suspending or cancelling a manufacturing licence requires the prescribed regulatory procedure to play out first — including the issuance of a show-cause notice. The Ministry’s stated concern is the gap this creates between the laboratory declaring a batch NSQ and any regulatory action taking effect.
In its own words, during that period “the drug may continue to remain in circulation, posing potential risks to public health and making effective recall more challenging.” A batch that has already failed government testing can, under current procedure, keep moving through distributors and pharmacies while paperwork is exchanged.
The draft directly attacks that window. There is no notice stage between the analyst’s certificate and the suspension order.
🔓 How a Suspension Gets Lifted
The draft is equally specific about the exit condition. New sub-rule (2AA) provides that suspension “may be revoked by the licensing authority only after the implementation of the Corrective Action and Preventive Action (CAPA) after its due verification by the said authority.”
In practical terms, three things must happen before a manufacturer resumes production of that drug:
- The manufacturer performs a root-cause analysis that actually identifies why the batch failed
- The manufacturer implements CAPA to the licensing authority’s satisfaction
- The licensing authority verifies on the ground that those measures are in place
The draft also inserts a proviso allowing the Central Licensing Approving Authority — in practice CDSCO — to demand the root-cause analysis, the CAPA plan, the investigation report and the final action taken by the State Licensing Authority. That proviso matters because manufacturing licences in India are issued by states while CDSCO runs the testing and the central approval track.
📨 Form 13 Gets Rewired: Who Receives the Test Report
One of the quieter but most operationally significant changes is to Form 13, the government analyst’s test report. Under the draft, every Form 13 will now carry a copy-to block naming three parties:
- The Drugs Controller General of India (DCGI)
- The State or Union Territory Drugs Controlling Authority with jurisdiction over the manufacturing site
- The manufacturer and the marketer named on the product label
This is not a cosmetic edit. It closes an accountability gap that Indian drug regulators have repeatedly flagged: a marketer named on the label can currently avoid direct regulatory visibility when the batch is manufactured by a third party. Routing the analyst’s report to both the manufacturer and the marketer puts the branded party on formal notice the same day the failure is recorded.
📊 The Numbers Behind the Draft
The proposal did not arrive in a vacuum. Data disclosed in Parliament and reported by ET Pharma in November 2026 shows the scale of the testing programme:
- 1.4 lakh (140,000) drug samples were tested by central and state laboratories in FY26
- 3,012 of those samples were found to be NSQ
- A further 283 were declared spurious or adulterated
- 779 prosecution cases were initiated
- 330 samples were flagged NSQ in the September cycle alone — the highest monthly tally of the year
According to CDSCO records cited by ET Pharma, the samples most commonly flagged are not obscure formulations: paracetamol, metformin combinations for diabetes, amoxicillin formulations, vitamin supplements and cough syrups. These are high-volume, low-margin products used daily by millions of patients.
Separately, the Drugs Controller General of India has said that more than 1,000 CAPA notices were issued over the past four years, with unsatisfactory responses across the board. That track record is the clearest argument for the draft’s core mechanism: if notices do not produce remediation, removing the notice stage removes the delay it created.
🩺 Industry Pushback: Risk-Based Safeguards Wanted
The proposal is not universally welcomed by manufacturers. Speaking to ET Pharma, an executive at a Mumbai-based pharmaceutical company raised a proportionality concern:
This is a good step from a patient safety point of view but the main concern is that the draft appears to mandate immediate suspension for any NSQ finding, without clearly distinguishing minor quality deviations from serious contamination or sterility failures. And this could lead to disproportionate action unless risk-based safeguards are introduced.
The objection has some substance. A dissolution failure on one batch and a sterility failure on an injectable are not the same public-health event, yet the draft as written triggers suspension identically for both. The 30-day comment window exists precisely to surface that kind of distinction, and the Ministry’s notification invites comments at drugsdiv-mohfw@gov.in or by post to the Under Secretary (Drugs), MoHFW, Upa Karan Bhawan, New Delhi.
Worth noting: a second, separate draft — G.S.R. 953(E), also dated 28 October 2026 — tightens Schedule M microbiological limits, moving the Grade A microbial limit from “less than 1 CFU” to “no growth,” aligned with WHO Technical Report Series No. 1044, Annex 2. The two drafts read together signal a broader tightening of India’s post-marketing quality regime.
🗳️ Legislative Route and Next Steps
- Parent statute: Drugs and Cosmetics Act, 1940 (Section 12(1) and Section 33(1) provide the rule-making power)
- Draft notified: G.S.R. 956(E), 28 October 2026; gazetted 29 October 2026; uploaded 4 November 2026
- Comment period: 30 days from the date the Gazette copies were made available to the public
- Origin: Deliberations at the 65th Drugs Consultative Committee meeting (20 December 2024) and recommendations of the 92nd Drugs Technical Advisory Board meeting (24 April 2025)
- Coming into force: Only on the date of final publication in the Official Gazette — the draft expressly states it is not yet operative
✅ What This Means for Buyers and Distributors
For anyone sourcing Indian generic medicines — whether a domestic pharmacy, a hospital procurement team or an overseas importer — the draft changes the practical meaning of an NSQ alert. Once finalised, an NSQ listing on one of the five critical parameters would no longer be a warning sign to watch; it would be an active suspension of that manufacturer’s licence for that drug.
- Track the monthly NSQ lists. CDSCO publishes monthly alerts identifying samples declared not of standard quality. Under the new regime, a listing on assay, dissolution, related substance, impurity or sterility carries immediate licensing consequence.
- Read Form 13 copies now. Marketers named on the label will receive the analyst’s report directly. Any supplier relationship where the marketer is a different entity from the manufacturer should be re-examined.
- Do not treat the draft as law yet. It comes into force only on final gazette publication. Until then, Rule 85’s show-cause procedure remains operative.
- Ask suppliers for CAPA documentation. The ability to produce a credible root-cause analysis and verified CAPA is now the direct route back to market access, not a goodwill gesture.
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
Sources
Primary source: Gazette of India, Extraordinary, Part II—Section 3—Sub-section (i), No. 855, 29 October 2026 — G.S.R. 956(E), Ministry of Health and Family Welfare (Department of Health and Family Welfare), dated 28 October 2026, [F. No. X11014/25/2026-DR], available via egazette.gov.in.
Reuters, “India proposes instant manufacturing licence suspension for drugs failing quality tests,” 4 November 2026. The Hindu, “Government proposes immediate suspension of manufacturing licences of substandard drugs,” 5 November 2026. Business Standard, “Govt proposes immediate licence suspension for substandard drugmakers,” 5 November 2026. ET Pharma, “Centre weighs immediate suspension of license for drugs flagged as NSQ,” 5 November 2026. CNBC-TV18 (Reuters), “India proposes instant manufacturing licence suspension for drugs failing quality tests,” 5 November 2026.
Note on figures: NSQ and spurious sample counts refer to FY26 testing by central and state laboratories as disclosed in Parliament. Monthly NSQ tallies are cycle-specific and states do not all report to CDSCO on a routine basis.
For more information, contact IMSDA at contact@indiamedicine.org.